PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TECHNOLOGY • Segmentation by technology • Comparison by technology • In-house – Market size and forecast 2017-2022 • Outsourced – Market size and forecast 2017-2022 • Market opportunity by technology PART 08: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • Biologics – Market size and forecast 2017-2022 • Biosimilars – Market size and forecast 2017-2022 • Market opportunity by product PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Rise in partnerships between traditional biopharma companies and biotechnology startups • Growing outsourcing of biologics manufacturing • Increase in FDA approvals for new biologics products PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amgen • F. Hoffmann-La Roche • Johnson & Johnson • Merck & Co. • Pfizer PART 16: APPENDIX • List of abbreviations Exhibit 01: Related market Exhibit 02: Market characteristics Exhibit 03: Market segments Exhibit 04: Market definition - Inclusions and exclusions checklist Exhibit 05: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Global – Market size and forecast 2017-2022 ($ bn) Exhibit 08: Global – Year-over-year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2017 Exhibit 17: Technology – Market share 2017-2022 (%) Exhibit 18: Comparison by technology Exhibit 19: In-house – Market size and forecast 2017-2022 ($ bn) Exhibit 20: In-house – Year-over-year growth 2018-2022 (%) Exhibit 21: Outsourced – Market size and forecast 2017-2022 ($ bn) Exhibit 22: Outsourced – Year-over-year growth 2018-2022 (%) Exhibit 23: Market opportunity by technology Exhibit 24: Product – Market share 2017-2022 (%) Exhibit 25: Comparison by product Exhibit 26: Biologics – Market size and forecast 2017-2022 ($ bn) Exhibit 27: Biologics – Year-over-year growth 2018-2022 (%) Exhibit 28: Biosimilars – Market size and forecast 2017-2022 ($ bn) Exhibit 29: Biosimilars – Year-over-year growth 2018-2022 (%) Exhibit 30: Market opportunity by product Exhibit 31: Customer landscape Exhibit 32: Global – Market share by geography 2017-2022 (%) Exhibit 33: Regional comparison Exhibit 34: Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 35: Americas – Year-over-year growth 2018-2022 (%) Exhibit 36: EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 37: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 38: APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 39: APAC – Year-over-year growth 2018-2022 (%) Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Vendor landscape Exhibit 43: Landscape disruption Exhibit 44: Vendors covered Exhibit 45: Vendor classification Exhibit 46: Market positioning of vendors Exhibit 47: Amgen: Overview Exhibit 48: Amgen – Business segments Exhibit 49: Amgen – Organizational developments Exhibit 50: Amgen – Geographic focus Exhibit 51: Amgen – Key offerings Exhibit 52: F. Hoffmann-La Roche: Overview Exhibit 53: F. Hoffmann-La Roche– Business segments Exhibit 54: F. Hoffmann-La Roche – Organizational developments Exhibit 55: F. Hoffmann-La Roche– Geographic focus Exhibit 56: F. Hoffmann-La Roche– Segment focus Exhibit 57: F. Hoffmann-La Roche – Key offerings Exhibit 58: Johnson & Johnson: Overview Exhibit 59: Johnson & Johnson– Business segments Exhibit 60: Johnson & Johnson – Organizational developments Exhibit 61: Johnson & Johnson – Geographic focus Exhibit 62: Johnson & Johnson – Segment focus Exhibit 63: Johnson & Johnson – Key offerings Exhibit 64: Merck & Co.: Overview Exhibit 65: Merck & Co. – Business segments Exhibit 66: Merck & Co. – Organizational developments Exhibit 67: Merck & Co. – Geographic focus Exhibit 68: Merck & Co. – Segment focus Exhibit 69: Merck & Co. – Key offerings Exhibit 70: Pfizer: Overview Exhibit 71: Pfizer – Business segments Exhibit 72: Pfizer – Organizational developments Exhibit 73: Pfizer – Geographic focus Exhibit 74: Pfizer – Segment focus Exhibit 75: Pfizer – Key offerings

Amgen F. Hoffmann-La Roche Johnson & Johnson Merck & Co Pfizer